Edwards resilia tissue aortic valve demonstrates favorable safety and efficacy at five years

Austin, texas, jan. 31, 2021 /prnewswire/ -- edwards lifesciences (nyse: ew) today announced new data from the commence clinical trial that demonstrate edwards' bioprosthetic surgical aortic valve with the company's novel resilia tissue platform show favorable safety and hemodynamic...
EW Ratings Summary
EW Quant Ranking